FCE-28260

FCE-28260
Clinical data
Routes of
administration
Oral
ATC code none
Identifiers
ChemSpider 117369
Chemical and physical data
Formula C28H35F3N2O2
Molar mass 488.58 g/mol
3D model (Jmol) Interactive image

FCE-28260 is a steroidal 5α-reductase inhibitor which was developed for the treatment of benign prostatic hyperplasia and androgenic alopecia (pattern hair loss) in the 1990s but was never marketed.[1][2] FCE-28260 has been found to inhibit rat and human 5α-reductase with half-maximal inhibitory concentrations (IC50) of 15 and 16 nM, respectively, while finasteride had values of 30 and 52 nM.[1]

References

  1. 1 2 Giudici, D.; Briatico, G.; Cominato, C.; Zaccheo, T.; Iehlè, C.; Nesi, M.; Panzeri, A.; Di Salle, E. (1996). "FCE 28260, a new 5 alpha-reductase inhibitor: In vitro and in vivo effects". The Journal of Steroid Biochemistry and Molecular Biology. 58 (3): 299–305. doi:10.1016/0960-0760(96)00040-4. PMID 8836165.
  2. EP 0782582, Salle Enrico Di, Marcella Nesi, Achille Panzeri, "Epimers of (22RS)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide", published 1997-07-09.



This article is issued from Wikipedia - version of the 11/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.